Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Allan JN"'
Autor:
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M
Publikováno v:
Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 10, Pp 1-5 (2020)
Chaitra Ujjani, 1 Anthony Mato, 2 Brian T Hill, 3 John N Allan, 4 Erick Lansigan, 5 Ryan Jacobs, 6 Hande Tuncer, 7 John Pagel, 8 Danielle Brander, 9 Bruce Cheson, 10 Paul Barr, 11 Lindsey E Roeker, 2 Jeffrey Pu, 12 Nirav N Shah, 13 Andre Goy, 14 Step
Externí odkaz:
https://doaj.org/article/55e83f385ab34228a9f4be53365dc63d
Autor:
Allan, JN, Shanafelt, T, Wiestner, A, Moreno, C, O'Brien, SM, Li, JL, Krigsfeld, G, Dean, JP, Ahn, IE
Publikováno v:
BRITISH JOURNAL OF HAEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::bd98128c4bf54823a02e4323e5cd84b5
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5181
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5181
Autor:
Arruga, F, Gizdic, B, Bologna, C, Cignetto, S, Buonincontri, R, Serra, S, Vaisitti, T, Vitale, N, Garaffo, G, Mereu, E, Diop, F, Neri, F, Coscia, M, Allan, Jn, Piva, R, Oliviero, S, Furman, Rr, Rossi, D, Gaidano, G, Deaglio, S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______970::678c35ea9e9f817daf68546bac3c6b81
http://hdl.handle.net/2318/1691085
http://hdl.handle.net/2318/1691085
Autor:
Torokaa PR; School of Public Health and Social Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.; Tanzania Field Epidemiology and Laboratory Training Program, Dar es Salaam, Tanzania., Urio L; Tanzania Field Epidemiology and Laboratory Training Program, Dar es Salaam, Tanzania., Mwakalobo A; Ministry of Health, Dodoma, Tanzania., Eriyo G; Ministry of Health, Dodoma, Tanzania., Magesa AS; Ministry of Health, Dodoma, Tanzania., Julius R; Ministry of Health, Dodoma, Tanzania., Kyalo A; Ministry of Health, Dodoma, Tanzania., Allan JN; School of Public Health and Social Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.; Tanzania Field Epidemiology and Laboratory Training Program, Dar es Salaam, Tanzania., Osima DJ; School of Public Health and Social Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.; Tanzania Field Epidemiology and Laboratory Training Program, Dar es Salaam, Tanzania., Shao FM; Clinton Health Access Initiative, Tanzania., Mziray J; Clinton Health Access Initiative, Tanzania., Mtui L; Clinton Health Access Initiative, Tanzania., Mbago TP; Clinton Health Access Initiative, Tanzania., Robert M; Ministry of Health, Directorate of Reproductive, Maternal and Child Health-Prevention of mother to child vertical transmission of HIV, Syphilis and Hepatitis B programme, Dodoma, Tanzania., Nyamhagatta MA; Ministry of Health, Directorate of Reproductive, Maternal and Child Health-Prevention of mother to child vertical transmission of HIV, Syphilis and Hepatitis B programme, Dodoma, Tanzania., Msangi M; Ministry of Health, Directorate of Reproductive, Maternal and Child Health-Prevention of mother to child vertical transmission of HIV, Syphilis and Hepatitis B programme, Dodoma, Tanzania., Chacha M; Ministry of Health, Directorate of Reproductive, Maternal and Child Health-Prevention of mother to child vertical transmission of HIV, Syphilis and Hepatitis B programme, Dodoma, Tanzania., Charles H; Ministry of Health, Directorate of Reproductive, Maternal and Child Health-Prevention of mother to child vertical transmission of HIV, Syphilis and Hepatitis B programme, Dodoma, Tanzania., Mtui GD; Ministry of Health, Directorate of Reproductive, Maternal and Child Health-Prevention of mother to child vertical transmission of HIV, Syphilis and Hepatitis B programme, Dodoma, Tanzania., Majigo M; College of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania., Joachim A; College of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Publikováno v:
HIV research & clinical practice [HIV Res Clin Pract] 2024 Dec; Vol. 25 (1), pp. 2378575. Date of Electronic Publication: 2024 Jul 16.
Autor:
Kittai AS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Allan JN; Weill Cornell Medicine, New York, NY., James D; Polaris Biostatistics Ltd, Edinburgh, United Kingdom., Bridge H; AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom., Miranda M; AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom., Yong ASM; AstraZeneca, Gaithersburg, MD., Fam F; AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom., Roos J; AstraZeneca, Gaithersburg, MD., Shetty V; AstraZeneca, Gaithersburg, MD., Skarbnik A; Novant Health Cancer Institute, Lymphoma and CLL Program, Charlotte, NC., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2024 Jun 11; Vol. 8 (11), pp. 2861-2869.
Autor:
Ghia P; Division of Experimental Oncology Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele Milan Italy., Owen C; Tom Baker Cancer Centre University of Calgary and Alberta Health Services Calgary Alberta Canada., Allan JN; Weill Cornell Medicine New York New York USA., Barrientos JC; Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center Miami Florida USA., Barr PM; Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA., Shi C; Biostatistics, Everest Clinical Research Owings Mills Maryland USA., Szoke A; AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA., Abbazio C; AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA., Krigsfeld GS; AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA., Burger JA; Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA.
Publikováno v:
HemaSphere [Hemasphere] 2024 May 27; Vol. 8 (5), pp. e74. Date of Electronic Publication: 2024 May 27 (Print Publication: 2024).
Autor:
Samples L; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Voutsinas J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Fakhri B; Division of Hematology and Oncology, University of California, San Francisco, CA., Khajavian S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Spurgeon S; Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR., Stephens D; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Skarbnik A; Novant Health, Charlotte, NC., Mato A; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Broome C; Division of Hematology and Oncology, Georgetown University, Washington, DC., Gopal A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Smith S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Lynch R; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Rainey M; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Kim MS; Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR., Barrett-Campbell O; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Hemond E; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Tsang M; Division of Hematology and Oncology, University of California, San Francisco, CA., Ermann D; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Malakhov N; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY., Rao D; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Shakib-Azar M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Morrigan B; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Chauhan A; Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, GA., Plate T; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Gooley T; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Ryan K; AstraZeneca, Gaithersburg, MD., Lansigan F; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Hill B; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Pongas G; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Parikh SA; Department of Hematology, Mayo Clinic, Rochester, MN., Roeker L; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Allan JN; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY., Cheng R; Division of Cardiology, University of Washington, Seattle, WA., Ujjani C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA.
Publikováno v:
Blood advances [Blood Adv] 2024 May 14; Vol. 8 (9), pp. 2085-2093.
Autor:
Jain N; The University of Texas MD Anderson Cancer Center, Houston, Texas., Croner LJ; AbbVie, North Chicago, Illinois.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Allan JN; Weill Cornell Medicine, New York, New York., Siddiqi T; City of Hope National Medical Center, Duarte, California., Tedeschi A; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Badoux XC; Ministry of Health, Kogarah, New South Wales, Australia., Eckert K; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Cheung LWK; AbbVie, North Chicago, Illinois.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Mukherjee A; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Dean JP; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Szafer-Glusman E; AbbVie, North Chicago, Illinois.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Seymour JF; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Feb 01; Vol. 30 (3), pp. 498-505.
Autor:
Marullo R; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Rutherford SC; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Revuelta MV; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Zamponi N; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Culjkovic-Kraljacic B; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Canada., Kotlov N; BostonGene Corporation, Waltham, Massachusetts., Di Siervi N; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Lara-Garcia J; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Allan JN; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Ruan J; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Furman RR; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Chen Z; Division of Biostatistics, Population Health Sciences Department, Weill Cornell Medicine, New York, New York., Shore TB; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Phillips AA; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Mayer S; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Hsu J; New York University Grossman School of Medicine, New York, New York., van Besien K; University Hospitals Seidman Cancer Center, Cleveland, Ohio., Leonard JP; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Borden KLB; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Canada., Inghirami G; Pathology and Laboratory Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Martin P; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Cerchietti L; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York.
Publikováno v:
Cancer research [Cancer Res] 2024 Jan 02; Vol. 84 (1), pp. 101-117.
Autor:
Chong SJF; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Zhu F; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Dashevsky O; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Mizuno R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Lai JX; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Hackett L; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Ryan CE; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Collins MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Iorgulescu JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Guièze R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Penailillo J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Carrasco R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Hwang YC; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Muñoz DP; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Bouhaddou M; Department of Microbiology, Immunology and Molecular Genetics, UCLA, Los Angeles, California, USA., Lim YC; Cancer Science Institute, National University of Singapore, Singapore., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Allan JN; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA., Furman RR; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA., Goh BC; Cancer Science Institute, National University of Singapore, Singapore., Pervaiz S; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Coppé JP; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2023 Nov 15; Vol. 133 (22). Date of Electronic Publication: 2023 Nov 15.